| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
LNA-Adenosine does not have a specific biological target like an enzyme or receptor. As a locked nucleic acid and adenosine analog, its primary application is in nucleic acid chemistry and as a building block for oligonucleotides. It can be incorporated into DNA or RNA sequences to increase their binding affinity and stability. Oligonucleotides modified with LNA units display greatly increased affinity toward nucleic acid targets, improved binding specificity, and enhanced enzymatic stability relative to unmodified strands. When metabolized to its triphosphate form (LNA-ATP), it can act as a competitive inhibitor of viral RNA-dependent RNA polymerases (RdRp).
|
|---|---|
| ln Vitro |
LNA-Adenosine, as a nucleoside analog, can exhibit antiviral activity. It shows an EC50 of >50 μM against wild-type Hepatitis C virus genotype 1b in human HuH7 cells. Its primary in vitro activity is related to its incorporation into nucleic acids, where it enhances stability and target binding affinity. LNA-Adenosine exhibits increased stability and binding affinity for complementary RNA sequences. Oligonucleotides modified with LNA units display greatly increased affinity toward nucleic acid targets, improved binding specificity, and enhanced enzymatic stability relative to unmodified strands.
|
| ln Vivo |
In vivo activity for LNA-Adenosine is not typically evaluated as a standalone therapeutic agent. Its effects are studied in the context of LNA-modified oligonucleotides, which can be used for various in vivo applications such as gene silencing or as aptamers. The LNA modification improves the pharmacokinetic properties of these oligonucleotides. 2'-O-methyl/locked nucleic acid (LNA) mixmer antisense oligonucleotides are potent and selective inhibitors of RNA editing on two different target RNAs.
|
| Enzyme Assay |
Specific protocols for enzyme/receptor binding assays for LNA-Adenosine are not applicable. As a nucleic acid analog, its interactions are studied in the context of hybridization to complementary RNA or DNA strands, often measured by melting temperature (Tm) assays to determine binding affinity. LNA-Adenosine exhibits increased stability and binding affinity for complementary RNA sequences.
|
| Cell Assay |
Cellular assays for LNA-Adenosine are typically conducted by incorporating it into oligonucleotides and studying their effects in cell-based systems. For example, its antiviral activity can be assessed in cells infected with a virus, such as the HCV assay in HuH7 cells where an EC50 of >50 μM was determined. 2'-O-methyl/locked nucleic acid (LNA) mixmer antisense oligonucleotides are potent and selective inhibitors of RNA editing on two different target RNAs.
|
| Animal Protocol |
In vivo studies for LNA-Adenosine are not conducted as a single agent. Instead, LNA-modified oligonucleotides are administered to animal models to study their therapeutic efficacy, pharmacokinetics, and biodistribution. The LNA modification enhances the stability and potency of these oligonucleotides in vivo. 2'-O-methyl/locked nucleic acid (LNA) mixmer antisense oligonucleotides are potent and selective inhibitors of RNA editing on two different target RNAs.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for LNA-Adenosine is not available. As a building block for oligonucleotides, its PK properties are not typically evaluated. However, LNA-modified oligonucleotides generally have improved pharmacokinetic properties, including increased stability against nucleases and longer half-lives.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for LNA-Adenosine is not available. As a research chemical, its safety profile is not well-characterized. Standard safety precautions for handling nucleic acid analogs should be followed.
|
| References | |
| Additional Infomation |
LNA-Adenosine is a research tool for nucleic acid chemistry and oligonucleotide-based therapeutics. It is not approved for clinical use. The locked nucleic acid modification enhances the stability and target binding affinity of oligonucleotides, making it a valuable tool for antisense, siRNA, and aptamer technologies. LNA-A serves as a critical building block for antisense oligonucleotides (ASOs), splice-switching oligos, aptamers, and diagnostic probes where enhanced target binding, nuclease resistance, and mismatch discrimination are required.
|
| Molecular Formula |
C11H13N5O4
|
|---|---|
| Molecular Weight |
279.26
|
| Exact Mass |
279.096
|
| CAS # |
206055-70-1
|
| PubChem CID |
44436074
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
660.0±65.0 °C at 760 mmHg
|
| Flash Point |
352.9±34.3 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.953
|
| LogP |
0.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@]2([C@H]([C@@H](O1)[C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)CO
|
| InChi Key |
GHKDRNDFVCEETA-KYAGDKKUSA-N
|
| InChi Code |
InChI=1S/C11H13N5O4/c12-8-5-9(14-3-13-8)16(4-15-5)10-6-7(18)11(1-17,20-10)2-19-6/h3-4,6-7,10,17-18H,1-2H2,(H2,12,13,14)/t6-,7+,10-,11+/m1/s1
|
| Chemical Name |
(1S,3R,4R,7S)-3-(6-aminopurin-9-yl)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-7-ol
|
| Synonyms |
LNA-A; LNA Adenosine; LNA-Adenosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5809 mL | 17.9045 mL | 35.8089 mL | |
| 5 mM | 0.7162 mL | 3.5809 mL | 7.1618 mL | |
| 10 mM | 0.3581 mL | 1.7904 mL | 3.5809 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
